Press release
Autistic Disorder Pipeline Insight Report 2023 | Major Companies- Scioto Biosciences, ACADIA Pharmaceuticals Inc., and others
In the Autistic Disorder Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Autistic disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Autistic Disorder Pipeline Report
• DelveInsight's Autistic Disorder Pipeline report depicts a robust space with 25+ active players working to develop 28+ pipeline therapies for autistic disorder treatment.
• The leading Autistic Disorder Companies include Scioto Biosciences, ACADIA Pharmaceuticals Inc., Yamo Pharmaceuticals LLC, Stalicla SA, MapLight Therapeutics, Jazz Pharmaceuticals, and others.
• Promising Autistic Disorder Pipeline include SB 121, Pimavanserin, FEN164, L1-79, ML-004, GWP42003-P, STP1, NTI164, AB-2004, RO7017773, INP105, PAX-101, SCI-210, Autologous MSC-NTF, ENT-01, MT 1988, IAMA-6, IAMA 097, MRx0006, and others.
• The Autistic Disorder Companies and academics are working to assess challenges and seek opportunities that could influence Autistic Disorder R&D. The therapies under development are focused on novel approaches for Autistic Disorder.
Request a sample and discover the recent advances in Autistic Disorder Drug Treatment @ Autistic Disorder Pipeline Report- https://www.delveinsight.com/sample-request/autistic-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Autistic Disorder Overview
Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by deficits in social communication and the presence of restricted interests and repetitive behaviors. There is no clear-cut pathology of ASD however different populations have been suggested for different subtypes of ASD.
Recent Developmental Activities in the Autistic Disorder Treatment Landscape
• In February 2023, PaxMedica, Inc., for the treatment of disorders with intractable neurologic symptoms, announced that the Company has signed a funding agreement for net proceeds of $3.2 million with Lind Global Partners II, LP, an investment fund managed by The Lind Partners, a New York based institutional fund manager (together "Lind"). This funding will give the flexibility to progress on the work PaxMedica are doing for the development of the autism spectrum disorder (ASD) indication for PAX-101. PaxMedica appreciates the Lind Group's support for work to find treatments for disorders with intractable neurologic symptoms such as ASD.
• In January 2023, SciSparc Ltd. announced it had signed an agreement with the Soroka University Medical Center, in Be'er-Sheva, Israel ("Soroka Medical Center") to conduct the Company's clinical study for SCI-210 in patients suffering from autism spectrum disorder ("ASD").
• In July 2022, Impel Pharmaceuticals announced the first subject had been dosed in a Phase IIa proof-of-concept study of INP105, nasal olanzapine, a widely used atypical, second-generation antipsychotic. INP105 is being developed as an acute treatment for agitation in persons with autism spectrum disorder (ASD) using Impel's proprietary Precision Olfactory Delivery (POD®) technology which delivers drugs to the upper nasal space.
• In May 2022, Scioto Biosciences, Inc. (Scioto) announced top-line results of its Phase Ib trial of lead asset SB-121, based on its novel microbiome delivery platform, Activated Bacterial Therapeutics (ABT), which is designed to deliver best-in-class, live therapeutic bacteria to the gut. This first-in-human study was a randomized, double-blind, placebo-controlled, 28-day daily-dose crossover study of the safety and tolerability of SB-121 (Lactobacillus reuteri with dextran microparticles and maltose) in patients ages 15 to 45 years, diagnosed with autism spectrum disorder (ASD).
• In February 2022, Axial Therapeutics announced the publication in Nature Medicine of full results from its Phase Ib/IIa clinical trial of AB-2004. AB-2004 was shown to have strong safety and tolerability across all dose levels, and no drug-related serious adverse events were identified. AB-2004 reduced anxiety and irritability based on scores on the Aberrant Behavior Checklist - Irritability domain (ABC-I) and the Pediatric Anxiety Rating Scale (PARS). Individuals with high baseline irritability (scores ≥ 15), which represents the top quartile of severity, displayed a greater than 9-point decrease in ABC-I over 8 weeks.
Find out more information of the latest Drugs Launch, News, and Breakthroughs of the Autistic Disorder Pipeline Report @ Latest Autistic Disorder Drugs Launch- https://www.delveinsight.com/sample-request/autistic-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Autistic Disorder Emerging Drugs Profile
• CM-AT: Curemark
CM-AT is designed to enhance protein digestion thereby potentially restoring the pool of essential amino acids. Essential amino acids play a critical role in the expression of several genes important to neurological function and serve as precursors to key neurotransmitters such as serotonin and dopamine. CM-AT, has received "Fast Track" designation from the U.S. Food and Drug Administration (FDA). FDA has also granted Curemark a rolling review of its New Drug Application for CM-AT.
• L1-79: Yamo pharmaceuticals
L1-79 is an investigational drug currently in clinical development by Yamo Pharmaceuticals for the treatment of the core symptoms of ASD. L1-79 was granted Fast Track Designation by the Food and Drug Administration in May of 2018. It acts as a tyrosine hydroxylase inhibitor and is expected to modulate the catecholaminergic pathways implicated in ASD. L1-79 reported positive results from Phase II study in November 2021. Clinical studies are planned to further investigate the potential of L1-79 to improve the core symptoms of ASD.
Autistic Disorder Pipeline Therapeutics Assessment
There are approx. 25+ key companies which are developing the Autistic Disorder. The companies which have their Autistic Disorder drug candidates in the most advanced stage, i.e. preregistration include, Curemark.
Learn more about the emerging Autistic Disorder pipeline therapies @ Autistic Disorder Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/autistic-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Autistic Disorder Pipeline
• Coverage- Global
• Autistic Disorder Companies- Scioto Biosciences, ACADIA Pharmaceuticals Inc., Yamo Pharmaceuticals LLC, Stalicla SA, MapLight Therapeutics, Jazz Pharmaceuticals, and others.
• Autistic Disorder Pipeline- SB 121, Pimavanserin, FEN164, L1-79, ML-004, GWP42003-P, STP1, NTI164, AB-2004, RO7017773, INP105, PAX-101, SCI-210, Autologous MSC-NTF, ENT-01, MT 1988, IAMA-6, IAMA 097, MRx0006, and others
• Autistic Disorder Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Dive deep into rich insights for drugs for Autistic Disorder Market Drivers and Autistic Disorder Market Barriers, click here @ Autistic Disorder Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/autistic-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Autistic disorder: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Autistic Disorder- DelveInsight's Analytical Perspective
7. Late Stage Products (Preregistration)
8. CM-AT: Curemark
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. L1-79: Yamo pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early stage products (Phase I)
14. SB-121: Scioto Biosciences
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Autistic disorder- Unmet Needs
18. Autistic disorder- Market Drivers and Barriers
19. Appendix
Got Queries? Find out the related information on Autistic Disorder Mergers and acquisitions, Autistic Disorder Licensing Activities @ Autistic Disorder Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/autistic-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Autistic Disorder Pipeline Insight Report 2023 | Major Companies- Scioto Biosciences, ACADIA Pharmaceuticals Inc., and others here
News-ID: 3005661 • Views: …
More Releases from DelveInsight Business Research
Geographic Atrophy Clinical Trial Analysis: 25+ Drugs, 23+ Companies Redefining …
DelveInsight's newly released report, "Geographic Atrophy Pipeline Insight" offers a comprehensive analysis of the evolving Geographic Atrophy (GA) therapeutic landscape, covering 23+ biopharmaceutical companies and 25 investigational drug candidates. The report features in-depth profiles of both clinical- and preclinical-stage assets, along with a detailed therapeutic assessment categorized by product type, development phase, route of administration, and molecular class. It also provides visibility into inactive and discontinued pipeline programs within the…
Interstitial Lung Disease Clinical Trial Analysis: 120+ Drugs and 120+ Companies …
DelveInsight, a prominent market intelligence and consulting organization in the life sciences domain, has announced the launch of its newest report titled "Interstitial Lung Disease Pipeline Insight, 2025." The publication delivers a comprehensive analysis of the fast-advancing therapeutic environment for Interstitial Lung Disease (ILD). With over 120 biopharmaceutical companies actively developing 120+ pipeline assets, the ILD pipeline is witnessing remarkable growth fueled by strong scientific innovation, clinical progress, and regulatory…
Global Vein Illumination Devices Market Forecast to Reach USD 152.83 Million by …
DelveInsight's latest publication, "Vein Illumination Devices Market Insights, Competitive Landscape and Market Forecast-2032," offers a comprehensive analysis of existing and future market dynamics. The report examines evolving trends, technological advancements, key market challenges, growth catalysts, and limiting factors, while also showcasing upcoming product launches and profiling the major players influencing the vein illumination devices industry.
Based on DelveInsight's most recent evaluation, the global vein illumination devices market is anticipated to experience…
Liver Cancer Clinical Trial Analysis: 75+ Drugs, 70+ Companies Redefining the Fu …
DelveInsight's "Liver Cancer Pipeline Insights 2025" delivers an in-depth overview of the liver cancer pipeline ecosystem, profiling more than 70 companies and 75+ therapeutic candidates under development. The report thoroughly examines liver cancer drug profiles across both clinical and preclinical stages. It also evaluates the therapeutic landscape by product category, development phase, route of administration, and molecular class, while additionally identifying inactive and discontinued assets within the pipeline.
Stay informed with…
More Releases for Autistic
Little Feet Pediatric Therapy Announces New Report Dispelling Myths About Autist …
Image: https://www.globalnewslines.com/uploads/2025/02/1739933336.jpg
Little Feet Pediatric Therapy, a leading DC pediatric rehabilitation therapy [https://littlefeettherapy.com/] clinic, is proud to announce the release of a new report aimed at dispelling common myths and misconceptions about autistic children. As experts in pediatric physical therapy [https://littlefeettherapy.com/services/physical-therapy/] and occupational therapy, the clinic seeks to provide parents with accurate, science-based information to help navigate their child's autism diagnosis and the challenges that may come with it.
The report, titled…
New Book Offers Hope and Encouragement to Parents of Autistic Children
No Ordinary Child: Living Life in the Face of Autism, has just been released on Amazon.com. Debbie Wilson, author of Sweet Scent of Justice, which was featured on the I.D. Channel’s, On the Case with Paula Zahn, has released the stirring, forthright account of her daughter’s courageous battle with autism and other disabilities from birth to adulthood. It will encourage parents as they read how her daughter, through her faith…
Hilton Pattaya’s Global Month of Service Builds a Playground for Autistic Chil …
Hilton Pattaya’s General Manager, Mr.Rudolf Troestler together with management team and hotel’s team members were recently welcomed by Khun Lampong Thongsong, Commander of Reconnoiter Battalion in the opening ceremony of pavilion and playground for autistic children at Hippotherapy Centre, Sattahip Naval Base.
In June this year, we started the ‘Bunny for Charity’ project in order to bring the funds raised from the sale of Bunny to build the playground and learning…
Are Autistic Traits in Youth Meaningful?
The Study Conducted at Massachusetts General Hospital (MGH) Suggests Association between Autistic Traits and ADHD Syndrome
Both attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) are known to have strong genetic elements. Individuals with ADHD may manifest different forms of ASD, from a fully developed to a milder appearance in a form of autistic traits. This fact was interesting to the group of researchers working at MGH of Harvard Medical School,…
Mom Wants Autistic Daughter to Wear GPS Tracker
A California mom wants approval for her autistic daughter to wear a GPS tracking device to school. She says it will prevent her child from wandering, but the school district is fighting that request.
The girl's mother, Darcy Cotton, said she does not sleep much."We are always exhausted and constantly living in a state of fear," she said.
For the past few years, the mother has been sleeping on the couch,…
Right Brain-Left Brain Connections in Autistic Kids
August 23, 2013: Behavioral scientists know that an ability to process "non-verbal" signals lays the foundation for developing both language and social skills. Dr. Yola Barbosa , a director at a Brain Balance Achievement Center in New Jersey notes, "The ability to process the non-verbal communication lays the foundation of social skills and language.
Kids with autism and even ADHD have a kind of social injury. They may…
